Matthew W. Strobeck - 31 May 2022 Form 4 Insider Report for Accelerate Diagnostics, Inc (AXDX)

Reporting relationship: Director
Issuer ticker: AXDX
Reported as of: 31 May 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 02 Jun 2022, 16:22:50 UTC
Prior SEC filing: 01 Jun 2022
Next SEC filing: 08 Jun 2022
Source filing: View source filing
Reporting owner signature: /s/ Steven Reichling, attorney-in-fact

Key filing fact

Matthew W. Strobeck filed Form 4 for Accelerate Diagnostics, Inc (AXDX) on 02 Jun 2022.

Key facts

This page summarizes Matthew W. Strobeck's Form 4 filing for Accelerate Diagnostics, Inc (AXDX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 02 Jun 2022, 16:22.

Change

Previous filing in this sequence was filed on 01 Jun 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AXDX transaction Derivative

Employee Restricted Stock Units

Award

Transaction value: $0
Shares: +75,949
Change %
Price: $0.000000
Shares after: 75,949
Date: 31 May 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 75,949
Exercise price
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.

Footnote F2

The restricted stock units vest in full on May 31, 2023. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. Pursuant to the issuer's Director Equity Deferral Program, the reporting person has elected to defer receipt of the shares of common stock upon vesting of the restricted stock units to such time that is within 30 days following his departure from the issuer's board of directors.

Footnote F3

Not applicable.